Outcomes following splenectomy in patients with myeloid neoplasms

Kristy L. Rialon, Paul J. Speicher, Eugene P. Ceppa, Victoria R. Rendell, Steven N. Vaslef, Anne Beaven, Douglas Tyler, Dan G. Blazer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background and Objectives: Myeloid neoplasms are classified into five major categories. These patients may develop splenomegaly and require splenectomy to alleviate mechanical symptoms, to ameliorate transfusion-dependent cytopenias, or to enhance stem cell transplantation. The objective of this study was to determine which clinical variables significantly impacted morbidity, mortality, and survival in patients with myeloid neoplasms undergoing splenectomy, and to determine if operative outcomes have improved over time. Methods: The records of all patients with myeloid neoplasms undergoing splenectomy from 1993 to 2010 were retrospectively reviewed. Results: Eighty-nine patients (n=89) underwent splenectomy for myeloid neoplasms. Over half of patients who had symptoms preoperatively had resolution of their symptoms post-splenectomy. The morbidity rate was 38%, with the most common complications being bleeding (14%) or infection (20%). Thirty-day mortality rate was 18% and median survival after splenectomy was 278 days. Decreased survival was associated with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, anemia, abnormal white blood cell count, and hypoalbuminemia. Patients who underwent stem cell transplantation did not show an increased risk for morbidity or mortality. Conclusions: Patients with myeloid neoplasms have a poor prognosis after splenectomy and the decision to operate is a difficult one, associated with high morbidity and mortality.

Original languageEnglish (US)
Pages (from-to)389-395
Number of pages7
JournalJournal of Surgical Oncology
Volume111
Issue number4
DOIs
StatePublished - Mar 1 2015
Externally publishedYes

Fingerprint

Splenectomy
Neoplasms
Morbidity
Mortality
Stem Cell Transplantation
Survival
Hypoalbuminemia
Myelodysplastic Syndromes
Splenomegaly
Leukocyte Count
Anemia
Hemorrhage
Infection

Keywords

  • Acute myeloid leukemia
  • Hypersplenism
  • Myelofibrosis
  • Myeloproliferative neoplasm
  • Splenomegaly

ASJC Scopus subject areas

  • Surgery
  • Oncology
  • Medicine(all)

Cite this

Rialon, K. L., Speicher, P. J., Ceppa, E. P., Rendell, V. R., Vaslef, S. N., Beaven, A., ... Blazer, D. G. (2015). Outcomes following splenectomy in patients with myeloid neoplasms. Journal of Surgical Oncology, 111(4), 389-395. https://doi.org/10.1002/jso.23846

Outcomes following splenectomy in patients with myeloid neoplasms. / Rialon, Kristy L.; Speicher, Paul J.; Ceppa, Eugene P.; Rendell, Victoria R.; Vaslef, Steven N.; Beaven, Anne; Tyler, Douglas; Blazer, Dan G.

In: Journal of Surgical Oncology, Vol. 111, No. 4, 01.03.2015, p. 389-395.

Research output: Contribution to journalArticle

Rialon, KL, Speicher, PJ, Ceppa, EP, Rendell, VR, Vaslef, SN, Beaven, A, Tyler, D & Blazer, DG 2015, 'Outcomes following splenectomy in patients with myeloid neoplasms', Journal of Surgical Oncology, vol. 111, no. 4, pp. 389-395. https://doi.org/10.1002/jso.23846
Rialon KL, Speicher PJ, Ceppa EP, Rendell VR, Vaslef SN, Beaven A et al. Outcomes following splenectomy in patients with myeloid neoplasms. Journal of Surgical Oncology. 2015 Mar 1;111(4):389-395. https://doi.org/10.1002/jso.23846
Rialon, Kristy L. ; Speicher, Paul J. ; Ceppa, Eugene P. ; Rendell, Victoria R. ; Vaslef, Steven N. ; Beaven, Anne ; Tyler, Douglas ; Blazer, Dan G. / Outcomes following splenectomy in patients with myeloid neoplasms. In: Journal of Surgical Oncology. 2015 ; Vol. 111, No. 4. pp. 389-395.
@article{abfd718fa724456194eda6951c32985f,
title = "Outcomes following splenectomy in patients with myeloid neoplasms",
abstract = "Background and Objectives: Myeloid neoplasms are classified into five major categories. These patients may develop splenomegaly and require splenectomy to alleviate mechanical symptoms, to ameliorate transfusion-dependent cytopenias, or to enhance stem cell transplantation. The objective of this study was to determine which clinical variables significantly impacted morbidity, mortality, and survival in patients with myeloid neoplasms undergoing splenectomy, and to determine if operative outcomes have improved over time. Methods: The records of all patients with myeloid neoplasms undergoing splenectomy from 1993 to 2010 were retrospectively reviewed. Results: Eighty-nine patients (n=89) underwent splenectomy for myeloid neoplasms. Over half of patients who had symptoms preoperatively had resolution of their symptoms post-splenectomy. The morbidity rate was 38{\%}, with the most common complications being bleeding (14{\%}) or infection (20{\%}). Thirty-day mortality rate was 18{\%} and median survival after splenectomy was 278 days. Decreased survival was associated with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, anemia, abnormal white blood cell count, and hypoalbuminemia. Patients who underwent stem cell transplantation did not show an increased risk for morbidity or mortality. Conclusions: Patients with myeloid neoplasms have a poor prognosis after splenectomy and the decision to operate is a difficult one, associated with high morbidity and mortality.",
keywords = "Acute myeloid leukemia, Hypersplenism, Myelofibrosis, Myeloproliferative neoplasm, Splenomegaly",
author = "Rialon, {Kristy L.} and Speicher, {Paul J.} and Ceppa, {Eugene P.} and Rendell, {Victoria R.} and Vaslef, {Steven N.} and Anne Beaven and Douglas Tyler and Blazer, {Dan G.}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/jso.23846",
language = "English (US)",
volume = "111",
pages = "389--395",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Outcomes following splenectomy in patients with myeloid neoplasms

AU - Rialon, Kristy L.

AU - Speicher, Paul J.

AU - Ceppa, Eugene P.

AU - Rendell, Victoria R.

AU - Vaslef, Steven N.

AU - Beaven, Anne

AU - Tyler, Douglas

AU - Blazer, Dan G.

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background and Objectives: Myeloid neoplasms are classified into five major categories. These patients may develop splenomegaly and require splenectomy to alleviate mechanical symptoms, to ameliorate transfusion-dependent cytopenias, or to enhance stem cell transplantation. The objective of this study was to determine which clinical variables significantly impacted morbidity, mortality, and survival in patients with myeloid neoplasms undergoing splenectomy, and to determine if operative outcomes have improved over time. Methods: The records of all patients with myeloid neoplasms undergoing splenectomy from 1993 to 2010 were retrospectively reviewed. Results: Eighty-nine patients (n=89) underwent splenectomy for myeloid neoplasms. Over half of patients who had symptoms preoperatively had resolution of their symptoms post-splenectomy. The morbidity rate was 38%, with the most common complications being bleeding (14%) or infection (20%). Thirty-day mortality rate was 18% and median survival after splenectomy was 278 days. Decreased survival was associated with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, anemia, abnormal white blood cell count, and hypoalbuminemia. Patients who underwent stem cell transplantation did not show an increased risk for morbidity or mortality. Conclusions: Patients with myeloid neoplasms have a poor prognosis after splenectomy and the decision to operate is a difficult one, associated with high morbidity and mortality.

AB - Background and Objectives: Myeloid neoplasms are classified into five major categories. These patients may develop splenomegaly and require splenectomy to alleviate mechanical symptoms, to ameliorate transfusion-dependent cytopenias, or to enhance stem cell transplantation. The objective of this study was to determine which clinical variables significantly impacted morbidity, mortality, and survival in patients with myeloid neoplasms undergoing splenectomy, and to determine if operative outcomes have improved over time. Methods: The records of all patients with myeloid neoplasms undergoing splenectomy from 1993 to 2010 were retrospectively reviewed. Results: Eighty-nine patients (n=89) underwent splenectomy for myeloid neoplasms. Over half of patients who had symptoms preoperatively had resolution of their symptoms post-splenectomy. The morbidity rate was 38%, with the most common complications being bleeding (14%) or infection (20%). Thirty-day mortality rate was 18% and median survival after splenectomy was 278 days. Decreased survival was associated with a diagnosis of myelodysplastic syndrome/myeloproliferative neoplasm, anemia, abnormal white blood cell count, and hypoalbuminemia. Patients who underwent stem cell transplantation did not show an increased risk for morbidity or mortality. Conclusions: Patients with myeloid neoplasms have a poor prognosis after splenectomy and the decision to operate is a difficult one, associated with high morbidity and mortality.

KW - Acute myeloid leukemia

KW - Hypersplenism

KW - Myelofibrosis

KW - Myeloproliferative neoplasm

KW - Splenomegaly

UR - http://www.scopus.com/inward/record.url?scp=84923779882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923779882&partnerID=8YFLogxK

U2 - 10.1002/jso.23846

DO - 10.1002/jso.23846

M3 - Article

VL - 111

SP - 389

EP - 395

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 4

ER -